Compare GSK plc (GSK) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ING Groep NV — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while ING Groep NV trades at $32.82 (market cap $94.33B). The key difference: GSK plc and ING Groep NV are close in size by market cap, and ING Groep NV pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| GSK | ING | |
|---|---|---|
Market Cap | $101.34B | $94.33B |
Sector | Health | Financials |
52-Week High | $61.18 | $33.31 |
52-Week Low | $36.20 | $22.67 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
ING trades at $32.75, up 1.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows solid fundamentals with a P/E of 13.36, net income margin of 27.84%, and a consistent earnings beat history in recent quarters. Recent corporate developments include a new subscription banking model and a dividend announcement for H1-2026.
The outlook is positive with strong analyst support (62.5% Buy rating) and DCF analyses suggesting intrinsic value above current price. Key opportunities include European rate environment benefits and strategic diversification, while risks involve significant negative operating cash flows and sensitivity to macroeconomic conditions affecting the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
